The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Consulting or Advisory Role - Castle Biosciences; Genentech; Merck
Research Funding - Amgen; Genentech; Merck; Pharmacyclics
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Novartis
Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM).
 
Stergios J. Moschos
No Relationships to Disclose
 
Shahneen Kaur Sandhu
Honoraria - Amgen; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Karl D. Lewis
No Relationships to Disclose
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Amgen; Biodesix; Novartis; Prometheus; Takeda; WorldCare Clinical, LLC
Research Funding - Amgen; BioMed Valley Discoveries; Deciphera; Lilly; Merck; Prometheus; Roche/Genentech
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Genoptix
Research Funding - Incyte
 
Yilong Zhang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Erik Rasmussen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Haby A. Henary
No Relationships to Disclose
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech